Tonsillectomy and immune therapy for high-risk IgA kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether removing the tonsils (tonsillectomy) plus immune-suppressing therapy can help people with a high-risk form of IgA nephropathy, a kidney disease. It aims to slow down kidney damage and delay the need for dialysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have IgA nephropathy confirmed by a kidney biopsy.
- Your urine protein level is more than 1 gram per day with visible blood in your urine.
- Or your urine protein is less than 1 gram per day with blood, and your risk of needing dialysis within 5 years is over 11% based on a special risk calculator.
- Your kidney biopsy shows certain active changes, such as cell growth or inflammation in the filtering units.
- You are between 18 and 75 years old.
- Your kidney function is above a certain level (eGFR greater than 20).
- You do not have diabetes, other kidney diseases, or other serious illnesses that could affect the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
This study tests an investigational drug (SCTC21C) for people with a type of autoimmune kidney disease called IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
Hear when a new Primary IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.